Immunogenicity for Biotherapeutics 2013

The leading event for biologics de-risking, immunoassay validation and predicting immunogenicity in novel, highly complex molecules

IIR's Immunogenicity for Biotherapeutics has 14 years of proven history for giving industry leaders the tools and expertise they need in order to best design their immunoassays, preclinical research pipelines and molecular de-risking strategies.

This year's agenda brings together industry experts with proven results on how to bridge both ever-present challenges of assay design and de-risking strategies for the next generation of molecular designs.

• Speakers
Amy Rosenberg, Director, Division of Therapeutic Proteins, FDA
Boris Gorovits, Director, Pharmacokinetics Pharmacodynamics & Metabolism, Pfizer
Bruce Torbett, Co-Director, CFAR & Proteomics Expresssion Core, Scripps Research Institute
Daniela Verthelyi, Chief, Laboratory of Immunology, FDA
David Peritt, Scientific Director, Immunology, Hospira
Don Zhong, Senior Scientist, Clinical Immunology, Amgen
Eric Furfine, President, R&D, Eleven Biotherapeutics
and many more.

Agenda topics
Fundamentals of Immunogenicity Assessment
Ongoing Assay Design and Modification Choices Throughout the Drug Development Life Cycle
Optimal Formats for Identifying and Quantifying NAb Response
and many more.